Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies
Journal of Diabetes Investigation · 2023
DOI: 10.1111/jdi.14015 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Sanbao Chai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Peking University International Hospital Research Grant.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/introduction Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus. Materials and Methods PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.
Results
Pooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.
Conclusions
Current evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
- Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
ORCID-Profile: Sanbao Chai
Förderung
- National Natural Science Foundation of China
- Peking University International Hospital Research Grant
Zitieren
APA
Chai, S., Liu, F., Yu, S., Yang, Z., & Sun, F. (2023). Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14015
Vancouver
Chai S, Liu F, Yu S, Yang Z, Sun F. Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.14015
BibTeX
@article{Chai2023,
author = {Chai, Sanbao and Liu, Fengqi and Yu, Shuqing and Yang, Zhirong and Sun, Feng},
title = {Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies},
journal = {Journal of Diabetes Investigation},
year = {2023},
doi = {10.1111/jdi.14015}
}
EUVIMED